Moderna, Inc. hopes to have its own vaccine candidate to protect against the omicron variant in clinical development within the next few weeks.
Moderna CEO Stephane Bancel said on Monday that the company expects to share data with its regulators around March after clinical development of the vaccine, according to Reuters.
PFIZER CEO SAYS VACCINE TO COMBAT OMICRON VARIANT WILL BE READY IN MARCH
The company is also working to develop a single-dose vaccine that combines a booster against COVID-19 with the flu shot, which Bancel said should be available by the fall of 2023 in some countries.
“Our goal is to be able to have a single annual booster so that we don’t have compliance issues where people don’t want to get two to three shots a winter,” she said, according to the outlet.
Pfizer announced earlier this month it expects to have a vaccine candidate to combat the omicron variant ready in March and has already started manufacturing doses of the vaccine.
CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER
Dr. Anthony Fauci, chief medical adviser and director of the National Institute of Allergy and Infectious Diseases, also spoke on the panel Monday, warning experts against approaching each variant with a “whack-a-mole” strategy.
Instead, he said they should try to “figure out what the mechanisms are that induces a response to a commonality among the potential variants we’re seeing and that can occur,” according to MarketWatch.
